Comparative Pharmacology
Head-to-head clinical analysis: DIONOSIL AQUEOUS versus GASTROVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIONOSIL AQUEOUS versus GASTROVIST.
DIONOSIL AQUEOUS vs GASTROVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DIONOSIL AQUEOUS contains propyliodone, a radiocontrast agent that absorbs X-rays, providing visualization of bronchial structures. It acts by coating the bronchial mucosa and filling the airways, allowing radiographic imaging.
Gastrovist (diatrizoate meglumine) is a iodinated radiographic contrast agent that attenuates X-rays, enhancing visualization of the gastrointestinal tract. It acts as a hyperosmolar agent, drawing fluid into the bowel lumen and providing positive contrast for imaging.
Intra-articular injection: 2-3 mL of 1% solution (20-30 mg) per joint; maximum 4 joints per session. Intravenous: 2-4 mL of 20% solution (400-800 mg) diluted in 20 mL water, administered slowly over 5-10 minutes, for peripheral angiography.
Oral: 50-100 mL of a 30% w/v solution (300 mg iodine/mL) administered orally 30-60 minutes before imaging. Repeat dose if necessary for adequate visualization. Rectal: 100-200 mL of a 30% w/v solution as enema for CT colonography.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is approximately 2 hours in patients with normal renal function (creatinine clearance >90 mL/min); prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion of unchanged drug accounts for >95% of elimination; <5% is eliminated via biliary/fecal routes.
Primarily renal (glomerular filtration): >95% of iodinated contrast is excreted unchanged in urine within 24 hours; <5% fecal or biliary.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent